Drugs / MenCC-BIO Vaccine
MenCC-BIO Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02858570 | Sep 2018 → May 2019 | meningococcal meningitis | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenCC-BIO Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02858570 ↗ |
| Known as | Bio-MenCC vaccine | “The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide...” NCT02858570 ↗ |
| Known as | MenCC-Bio | “Vaccine against meningococcus serogroup C conjugated to tetanus toxoid produced by Bio-Manguinhos / FIOCRUZ (MenCC-Bio).” NCT02858570 ↗ |
| Modality | Vaccine | “The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein” NCT02858570 ↗ |